Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source
Recruiting
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
NCT07827599· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155· Phase 2· Shanghai Escugen Biotechnology Co., Ltd· Source
Recruiting
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596· Phase 1/2· Climb Bio, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Not yet recruiting
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT07381582· Early phase 1· Peking Union Medical College Hospital· Source
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042· Phase 1/2· Sinocelltech Ltd.· Source
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke
NCT06360458· Phase 3· Wan-Jin Chen· Source
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
NCT06155084· Phase 1/2· Hinova Pharmaceuticals Inc.· Source
Not yet recruiting
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· Phase 3· Akeso· Source
Recruiting
Clinical Study of Oncolytic Virus in Glioblastoma
NCT07145047· Phase 1/2· Mianyang Central Hospital· Source
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Recruiting
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
NCT06569524· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· Phase 3· AbbVie· Source
Recruiting
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
NCT05590871· Shanghai Hongdian Medical CO., LTD· Source
Active, not recruiting
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894· Phase 3· Taizhou Hanzhong biomedical co. LTD· Source
Recruiting
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
NCT05334277· Phase 2· Sun Yat-sen University· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
NCT04906434· Phase 1· Abbisko Therapeutics Co, Ltd· Source
Active, not recruiting
KN035 for dMMR/MSI-H Advanced Solid Tumors
NCT03667170· Phase 2· 3D Medicines (Sichuan) Co., Ltd.· Source